Hologic (HOLX) : Analyst Rating Update

Hologic (HOLX) : The consensus on Hologic (HOLX) based on 16 analyst recommendation on the company stock is 1.88, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 2 which endorses a Buy on the stock. However, 9 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 7 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Hologic (HOLX) : 12 Wall Street analysts covering Hologic (HOLX) believe that the average level the stock could reach for the short term is $42.25. The maximum price target given is $46 and the minimum target for short term is around $38, hence the standard deviation is calculated at $2.56.

Hologic (NASDAQ:HOLX): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $34.38 and $34.21 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $34.74. The buying momentum continued till the end and the stock did not give up its gains. It closed at $34.70, notching a gain of 0.75% for the day. The total traded volume was 2,233,704 . The stock had closed at $34.44 on the previous day.

Also, Brokerage firm Needham downgrades its rating on Hologic (NASDAQ:HOLX). The shares have been rated Hold. Previously, the analysts had a Buy rating on the shares. The rating by the firm was issued on April 28, 2016. The company shares have dropped -8.89% from its 1 Year high price. On Aug 18, 2015, the shares registered one year high at $43.00 and the one year low was seen on Feb 12, 2016. The 50-Day Moving Average price is $33.99 and the 200 Day Moving Average price is recorded at $35.00.

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products. The Companys business units are focused on diagnostics, breast health, GYN surgical and skeletal health. The Companys diagnostics products include Aptima family of assays, its ThinPrep system, the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases, chlamydia and gonorrhea, certain high-risk strains of human papillomavirus (HPV), and Trichomonas vaginalis, the parasite that causes trichomoniasis. The Companys GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems, an ultrasound-based osteoporosis assessment product, and its Fluoroscan mini C-arm imaging products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.